Risk of Hypogonadism From Scatter Radiation During Pelvic Radiation in Male Patients With Rectal Cancer

Ivan Yau, Té Vuong, Aurélie Garant, Thierry Ducruet, Patrick Doran, Sergio Faria, Sender Liberman, Carole Richard, François Letellier, Patrick Charlebois, Rasmy Loungnarath, Barry Stein, Slobodan Devic

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: Recent studies have reported fluctuations in sex hormones during pelvic irradiation. The objective of this study was to observe the effects of radiation on hormonal profiles for two treatment modalities: conventional external beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDRBT) given neoadjuvantly for patients with rectal cancer. Methods and Materials: Routine serum follicle stimulating hormone (FSH), luteinizing hormone (LH), and testosterone levels were collected from 119 consecutive male patients receiving either EBRT, using 45.0-50.4 Gy in 25-28 fractions with concurrent 5-fluorouracil chemotherapy or HDRBT using 26 Gy in 4 fractions. Results: Thirty patients with initially abnormal profiles were excluded. Profiles included in this study were collected from 51 patients treated with EBRT and 38 patients treated with HDRBT, all of whom had normal hormonal profiles before treatment. Mean follow-up times were 17 months for the entire patient cohort-14 and 20 months, respectively-for the EBRT and HDRBT arms. Dosimetry results revealed a mean cumulative testicular dose of 1.24 Gy received in EBRT patients compared with 0.27 Gy in the HDRBT group. After treatment, FSH and LH were elevated in all patients but were more pronounced in the EBRT group. The testosterone-to-LH ratio was significantly lower (p = 0.0036) in EBRT patients for tumors in the lower third of the rectum. The 2-year hypogonadism rate observed was 2.6% for HDRBT compared with 17.6% for EBRT (p = 0.09) for tumors in the lower two thirds of the rectum. Conclusion: HDRBT allows better hormonal sparing than EBRT during neoadjuvant treatment of patients with rectal cancer.

Original languageEnglish (US)
Pages (from-to)1481-1486
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume74
Issue number5
DOIs
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Hypogonadism
Rectal Neoplasms
Brachytherapy
radiation therapy
cancer
Radiotherapy
Radiation
hormones
radiation
dosage
Luteinizing Hormone
rectum
Follicle Stimulating Hormone
profiles
Rectum
Testosterone
tumors
Neoadjuvant Therapy
Radiation Effects
Gonadal Steroid Hormones

Keywords

  • External beam radiotherapy
  • High-dose-rate brachytherapy
  • Hormones
  • Rectal cancer

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Risk of Hypogonadism From Scatter Radiation During Pelvic Radiation in Male Patients With Rectal Cancer. / Yau, Ivan; Vuong, Té; Garant, Aurélie; Ducruet, Thierry; Doran, Patrick; Faria, Sergio; Liberman, Sender; Richard, Carole; Letellier, François; Charlebois, Patrick; Loungnarath, Rasmy; Stein, Barry; Devic, Slobodan.

In: International Journal of Radiation Oncology Biology Physics, Vol. 74, No. 5, 01.08.2009, p. 1481-1486.

Research output: Contribution to journalArticle

Yau, I, Vuong, T, Garant, A, Ducruet, T, Doran, P, Faria, S, Liberman, S, Richard, C, Letellier, F, Charlebois, P, Loungnarath, R, Stein, B & Devic, S 2009, 'Risk of Hypogonadism From Scatter Radiation During Pelvic Radiation in Male Patients With Rectal Cancer', International Journal of Radiation Oncology Biology Physics, vol. 74, no. 5, pp. 1481-1486. https://doi.org/10.1016/j.ijrobp.2008.10.011
Yau, Ivan ; Vuong, Té ; Garant, Aurélie ; Ducruet, Thierry ; Doran, Patrick ; Faria, Sergio ; Liberman, Sender ; Richard, Carole ; Letellier, François ; Charlebois, Patrick ; Loungnarath, Rasmy ; Stein, Barry ; Devic, Slobodan. / Risk of Hypogonadism From Scatter Radiation During Pelvic Radiation in Male Patients With Rectal Cancer. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 74, No. 5. pp. 1481-1486.
@article{3822567f0a904088a1d12ad778aabcef,
title = "Risk of Hypogonadism From Scatter Radiation During Pelvic Radiation in Male Patients With Rectal Cancer",
abstract = "Purpose: Recent studies have reported fluctuations in sex hormones during pelvic irradiation. The objective of this study was to observe the effects of radiation on hormonal profiles for two treatment modalities: conventional external beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDRBT) given neoadjuvantly for patients with rectal cancer. Methods and Materials: Routine serum follicle stimulating hormone (FSH), luteinizing hormone (LH), and testosterone levels were collected from 119 consecutive male patients receiving either EBRT, using 45.0-50.4 Gy in 25-28 fractions with concurrent 5-fluorouracil chemotherapy or HDRBT using 26 Gy in 4 fractions. Results: Thirty patients with initially abnormal profiles were excluded. Profiles included in this study were collected from 51 patients treated with EBRT and 38 patients treated with HDRBT, all of whom had normal hormonal profiles before treatment. Mean follow-up times were 17 months for the entire patient cohort-14 and 20 months, respectively-for the EBRT and HDRBT arms. Dosimetry results revealed a mean cumulative testicular dose of 1.24 Gy received in EBRT patients compared with 0.27 Gy in the HDRBT group. After treatment, FSH and LH were elevated in all patients but were more pronounced in the EBRT group. The testosterone-to-LH ratio was significantly lower (p = 0.0036) in EBRT patients for tumors in the lower third of the rectum. The 2-year hypogonadism rate observed was 2.6{\%} for HDRBT compared with 17.6{\%} for EBRT (p = 0.09) for tumors in the lower two thirds of the rectum. Conclusion: HDRBT allows better hormonal sparing than EBRT during neoadjuvant treatment of patients with rectal cancer.",
keywords = "External beam radiotherapy, High-dose-rate brachytherapy, Hormones, Rectal cancer",
author = "Ivan Yau and T{\'e} Vuong and Aur{\'e}lie Garant and Thierry Ducruet and Patrick Doran and Sergio Faria and Sender Liberman and Carole Richard and Fran{\cc}ois Letellier and Patrick Charlebois and Rasmy Loungnarath and Barry Stein and Slobodan Devic",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.ijrobp.2008.10.011",
language = "English (US)",
volume = "74",
pages = "1481--1486",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Risk of Hypogonadism From Scatter Radiation During Pelvic Radiation in Male Patients With Rectal Cancer

AU - Yau, Ivan

AU - Vuong, Té

AU - Garant, Aurélie

AU - Ducruet, Thierry

AU - Doran, Patrick

AU - Faria, Sergio

AU - Liberman, Sender

AU - Richard, Carole

AU - Letellier, François

AU - Charlebois, Patrick

AU - Loungnarath, Rasmy

AU - Stein, Barry

AU - Devic, Slobodan

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Purpose: Recent studies have reported fluctuations in sex hormones during pelvic irradiation. The objective of this study was to observe the effects of radiation on hormonal profiles for two treatment modalities: conventional external beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDRBT) given neoadjuvantly for patients with rectal cancer. Methods and Materials: Routine serum follicle stimulating hormone (FSH), luteinizing hormone (LH), and testosterone levels were collected from 119 consecutive male patients receiving either EBRT, using 45.0-50.4 Gy in 25-28 fractions with concurrent 5-fluorouracil chemotherapy or HDRBT using 26 Gy in 4 fractions. Results: Thirty patients with initially abnormal profiles were excluded. Profiles included in this study were collected from 51 patients treated with EBRT and 38 patients treated with HDRBT, all of whom had normal hormonal profiles before treatment. Mean follow-up times were 17 months for the entire patient cohort-14 and 20 months, respectively-for the EBRT and HDRBT arms. Dosimetry results revealed a mean cumulative testicular dose of 1.24 Gy received in EBRT patients compared with 0.27 Gy in the HDRBT group. After treatment, FSH and LH were elevated in all patients but were more pronounced in the EBRT group. The testosterone-to-LH ratio was significantly lower (p = 0.0036) in EBRT patients for tumors in the lower third of the rectum. The 2-year hypogonadism rate observed was 2.6% for HDRBT compared with 17.6% for EBRT (p = 0.09) for tumors in the lower two thirds of the rectum. Conclusion: HDRBT allows better hormonal sparing than EBRT during neoadjuvant treatment of patients with rectal cancer.

AB - Purpose: Recent studies have reported fluctuations in sex hormones during pelvic irradiation. The objective of this study was to observe the effects of radiation on hormonal profiles for two treatment modalities: conventional external beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDRBT) given neoadjuvantly for patients with rectal cancer. Methods and Materials: Routine serum follicle stimulating hormone (FSH), luteinizing hormone (LH), and testosterone levels were collected from 119 consecutive male patients receiving either EBRT, using 45.0-50.4 Gy in 25-28 fractions with concurrent 5-fluorouracil chemotherapy or HDRBT using 26 Gy in 4 fractions. Results: Thirty patients with initially abnormal profiles were excluded. Profiles included in this study were collected from 51 patients treated with EBRT and 38 patients treated with HDRBT, all of whom had normal hormonal profiles before treatment. Mean follow-up times were 17 months for the entire patient cohort-14 and 20 months, respectively-for the EBRT and HDRBT arms. Dosimetry results revealed a mean cumulative testicular dose of 1.24 Gy received in EBRT patients compared with 0.27 Gy in the HDRBT group. After treatment, FSH and LH were elevated in all patients but were more pronounced in the EBRT group. The testosterone-to-LH ratio was significantly lower (p = 0.0036) in EBRT patients for tumors in the lower third of the rectum. The 2-year hypogonadism rate observed was 2.6% for HDRBT compared with 17.6% for EBRT (p = 0.09) for tumors in the lower two thirds of the rectum. Conclusion: HDRBT allows better hormonal sparing than EBRT during neoadjuvant treatment of patients with rectal cancer.

KW - External beam radiotherapy

KW - High-dose-rate brachytherapy

KW - Hormones

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=67651113764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651113764&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.10.011

DO - 10.1016/j.ijrobp.2008.10.011

M3 - Article

C2 - 19147304

AN - SCOPUS:67651113764

VL - 74

SP - 1481

EP - 1486

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -